Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

'The Rheumatoid Arthritis Drugs Market Generated $12.7bn in 2010' Says visiongain Report


News provided by

Visiongain Ltd

08 Sep, 2011, 10:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, September 8, 2011 /PRNewswire/ --

http://www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-Drug-Market-2011-2021

A new report by visiongain, a London-based business information company, predicts that world revenues for rheumatoid arthritis drugs will rise strongly between 2011 and 2021. This market will grow to reach $17.3bn in 2015. The rheumatoid arthritis drugs market generated $12.7bn in 2010, according to Rheumatoid Arthritis: World Drug Market 2011-2021, published in September 2011.

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which skeletal joints become inflamed, causing pain, swelling and stiffness. RA can affect a person's ability to carry out everyday tasks. It is not known why rheumatoid arthritis develops, and there is no cure. Understanding of the disease has improved, however, and there are treatments that ease the pain and other symptoms, managing the disease.

Diya Lahiri, pharmaceutical industry analyst, said: "The world rheumatoid arthritis treatments market will benefit from the entry of new drugs this decade. There are prominent needs in the RA market, the most important being the development of drugs that are truly disease modifying rather than merely symptom managing. R&D efforts will help develop novel treatments that will not only benefit patients but also help researchers understand rheumatoid arthritis better."

Visiongain forecasts that the rheumatoid arthritis drug market will expand steadily to 2021. The future of the market is promising, with increasing demand for novel treatments such as biological drugs. The prospect of newer, more-effective drugs for RA, such as anti-TNF agents, will help this market to grow further. This new study adds to visiongain's wide range of analytical reports in healthcare and other industry areas.

To view sample pages please click on:

http://www.visiongain.com/Report/679/Rheumatoid-Arthritis-World-Drug-Market-2011-2021

For an exec summary please email Sara Peerun

Email: sara.peerun@visiongainglobal.com
Tel: +44(0)207-3366100
Web: http://www.visiongain.com

Table of Contents

1. Executive Summary
1.1 World Rheumatoid Arthritis Treatments Market Outlook
1.2 Aims Scope and Format of the Report
1.3 Research and Analysis Methods
1.4 Chapter Outlines

2. Introduction to Rheumatoid Arthritis
2.1 What is Rheumatoid Arthritis?
2.2 Understanding Joints
2.3 What Causes Rheumatoid Arthritis?
2.3.1 Overactive Immune System: The Immune Response and Inflammation Process
2.3.2 Genetic Factors
2.3.3 Environmental Triggers
2.4 Diagnosis of Rheumatoid Arthritis
2.4.1 Radiographic Features of Rheumatoid Arthritis
2.4.2 Blood Tests
2.4.3 Disorders with Similar Symptoms
2.5 Disease Risk Factors
2.6 Managing Rheumatoid Arthritis
2.6.1 Main Treatments Offered
2.6.2 Other Treatments Offered
2.6.3 Diet and Complementary Therapies
2.6.4 Surgical Options
2.6.5 Monitoring Disease Progression
2.7 Economic Costs of Rheumatoid Arthritis
2.8 World Prevalence of Rheumatoid Arthritis
2.9 Uncertainty on the Incidence of Rheumatoid Arthritis

3. Treatments for Rheumatoid Arthritis
3.1 What Drugs Are Used to Treat RA?
3.2 Pain Relieving Drugs
3.2.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
3.2.2 Side-Effects of NSAIDs
3.3 Corticosteroids
3.4 Disease Modifying Anti-Rheumatic Drugs (DMARDs)
3.4.1 Methotrexate
3.4.2 Biologics
3.4.3 Hydroxychloroquine and Sulfasalazine
3.4.4 Minocycline
3.4.5 Leflunomide
3.4.6 Cyclosporine
3.4.7 Azathioprine
3.5 Biologics for Rheumatoid Arthritis Treatment
3.5.1 What is Tumour Necrosis Factor?
3.5.2 Side-Effects of Biologics
3.5.3 Combining Biologics with DMARDs
3.6 Key Treatments in the RA Drug Market

4. The Global Rheumatoid Arthritis Drug Market, 2011-2021
4.1 The Global Rheumatoid Arthritis Market, 2011-2021
4.2 Non-Biologics for RA
4.2.1 NSAIDs: Market Forecast, 2011-2021
4.2.2 Other Non-Biologics for RA: Market Forecast, 2011-2021
4.3 Biologics for RA: Market Forecast 2011-2021
4.3.1True Contribution of Biologics in the RA Market
4.4 Summary of the Market

5. Main Drugs in the Rheumatoid Arthritis Market, 2011-2021
5.1 Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.1.1 Celebrex (Pfizer): Market Forecast, 2011-2021
5.1.1.1 Development of Celebrex
5.1.2 Arcoxia (Merck and Co.): Market Forecast, 2011-2021
5.1.2.1 Development of Arcoxia
5.2 Biologics for RA Treatments
5.2.1 Humira (Abbott Laboratories): Market Forecast, 2011-2021
5.2.1.1 Long Term Prospects for Humira
5.2.2 Remicade (Johnson and Johnson): Market Forecast, 2011-2021
5.2.2.1 Long Term Prospects for Remicade
5.2.3 Enbrel (Amgen; Pfizer; Takeda): Market Forecast, 2011-2021
5.2.3.1 Amgen Continues to Benefit from Enbrel Sales
5.2.3.2 Enbrel Sales Will Show an Initial Increase
5.2.3.3 Study Eases Fears of TNF Blocker Cancer Risk
5.2.3.4 New Enbrel Delivery System
5.2.3.5 Sales of Enbrel Will Eventually Decline
5.2.3.6 Enbrel Faces Competition from Several Other Biotech Drugs
5.2.4 MabThera (Rituxan in the US - Roche; Biogen Idec): Market Forecast, 2011-2021
5.2.4.1MabThera: Leading Biologic for RA
5.2.5 Orencia (Bristol-Myers Squibb): Market Forecast, 2011-2021
5.2.5.1 Orencia: New Biologic for RA
5.2.6 Actemra (Roche): Market Forecast, 2011-2021
5.2.6.1 Actemra Will Achieve Growth
5.2.7 Cimzia (UCB): Market Forecast, 2011-2021
5.2.7.1 Cimzia: Forecast and Analysis, 2011-2021
5.2.8 Kineret (Biovitrium): Future Prospects
5.2.9 Simponi (Johnson and Johnson): Future Prospects

6. R&D Pipeline for Rheumatoid Arthritis Drugs, 2011
6.1 R&D Pipeline: NSAIDs for Rheumatoid Arthritis, 2011
6.1.1 Famotidine + Ibuprofen (Horizon)
6.1.2 Ibuprofen-PC (PLx Pharma)
6.1.3 Apricoxib (Tragara; Daiichi Sankyo)
6.1.4 CEP 33222 (Cephalon; Acusphere)
6.2 R&D Pipeline: Corticosteroids for Rheumatoid Arthritis, 2011
6.2.1 Lodotra (Horizon; SkyePharma)
6.3 R&D Pipeline: Biologics to Treat Rheumatoid Arthritis, 2011
6.3.1 Denosumab (Amgen)
6.3.2 Fostamatinib (AstraZeneca)
6.3.3 Tofacitinib (Pfizer)
6.3.4 Ofatumumab (Genmab; GSK)
6.3.5 Masitinib (AB Science)
6.3.6 Belimumab (GSK; Human Genome Sciences)
6.3.7 Canakinumab (Novartis)
6.3.8 Baminercept Alfa (Biogen Idec)
6.3.9 Ocrelizumab (Roche)
6.3.10 Sarilumab (Regeneron; Sanofi)
6.3.11 dnaJP1 (Adeona)
6.3.12 T-5224 (Roche; Toyoma Chemicals)
6.3.13 Anti- BAFF Monoclonal Antibody (Eli Lilly)
6.3.14 Olokizumab (UCB)
6.3.15 Anti-IL-17 Monoclonal Antibody (Eli Lilly)
6.3.16 JAK1/JAK2 Inhibitor (Eli Lilly)
6.3.17 Sirukumab (Johnson and Johnson)
6.3.18 INCB018424 (Incyte Corporation)
6.3.19 ALD 518 (Bristol Myers Squibb; Alder Biopharmaceuticals)
6.3.20 GSK3152314A (GlaxoSmithKline)
6.3.21 RPI-MN (ReceptoPharm)
6.3.22 MT203 (Nycomed)

7. Leading National Markets for Rheumatoid Arthritis Treatments, 2011-2021
7.1 Leading National Markets for Rheumatoid Arthritis, 2010-2021
7.2 The US Rheumatoid Arthritis Market, 2011-2021
7.3 The Japanese Rheumatoid Arthritis Market, 2011-2021
7.4 The Leading European Markets for Rheumatoid Arthritis Treatments, 2011-2021
7.5 Rheumatoid Arthritis Drug Market in Emerging Economies, 2011-2021
7.5.1 The Chinese Rheumatoid Arthritis Market, 2011-2021
7.5.2 The Indian Rheumatoid Arthritis Market, 2011-2021
7.6 Rheumatoid Arthritis Treatments in the Rest of the World, 2011-2021
7.7 Summary of National Market Forecasts

8. Leading Companies in the Rheumatoid Arthritis Drug Market, 2011
8.1 Introduction
8.2 Roche
8.3 Abbott Laboratories
8.4 Amgen
8.5 Johnson & Johnson
8.6 Biogen Idec

9. Drivers and Restraints in the Rheumatoid Arthritis Drug Market
9.1 SWOT Analysis of the RA Drug Market
9.2 Commercial Drivers in the RA Drug Market
9.2.1 The Biological Drug Market for RA is Well-Established
9.2.2 New Product Development Will Drive the RA Market
9.2.3 Rising Prevalence of RA Will Enhance Market Growth
9.2.4 Small Molecules Will Have a Positive Impact on RA Treatments
9.2.5 Revised Treatment Classification Criteria Will Make Diagnosis Easier
9.3 Commercial Restraints in the RA Drug Market
9.3.1 Biological Drugs - Too Costly in Most Countries?
9.3.2 The Biological Drug Industry - Insufficiently Dynamic?
9.3.3 Unmet Clinical Needs in Rheumatoid Arthritis Treatment Will Slow Growth
9.3.4 Biosimilar Competition May Restrain the RA Market for Biologics
9.3.5 Side-Effects and Costly Treatments
9.3.6 Inadequate Reimbursement for Biologics Will Hamper RA Market Growth
9.4 Concluding Remarks

10. Research Interviews
10.1 Interview 1: Dr Yusuf Yazici, MD, Assistant Professor, Department of Medicine-Rheumatology and Hospital for Joint Diseases and Medicine, New York University
10.1.1 Opinion on the Key Unmet Needs for RA Treatments
10.1.2 Opinions on Current Treatments
10.1.3 Views on Abatacept: New Biologic for RA
10.1.4 Key Challenges: Development and Uptake of Abatacept
10.1.5 Views on Cimzia
10.1.6 Treatments in the R&D Pipeline
10.1.7 Views on the Prevalence of RA
10.2 Interview 2: A Professor Working in Rheumatology
10.2.1 Views on the Prevalence of RA
10.2.2 Views on Anti-TNF Therapies for RA
10.2.3 Opinion on Biosimilars
10.2.4 Key Challenges in the Market
10.2.5 Key Treatment Goals

11. Conclusions
11.1 The RA Market - Revenue Growth
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in RA Treatments
11.5 Future Rheumatoid Arthritis Treatments: R&D Efforts Promising
11.6 The RA Treatments Sector: Looking into the Future Confidently



Notes for Editors


About visiongain


Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.